Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8+ T-cell immunity

被引:18
|
作者
Brown, Matthew D. [1 ]
van der Most, Robbert [2 ]
Vivian, Justin B. [3 ]
Lake, Richard A. [4 ]
Larma, Irma [1 ]
Robinson, Bruce W. S. [4 ]
Currie, Andrew J. [4 ,5 ]
机构
[1] Sir Charles Gairdner Hosp, Urol Res Ctr, Univ Dept Surg, Perth, WA, Australia
[2] GSK Biol, Rixensart, Belgium
[3] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia
[4] Univ Western Australia, Natl Res Ctr Asbestos Related Dis, Perth, WA 6009, Australia
[5] Murdoch Univ, Sch Vet & Biomed Sci, Perth, WA, Australia
来源
ONCOIMMUNOLOGY | 2012年 / 1卷 / 07期
基金
英国医学研究理事会;
关键词
CD8(+) T cell; cross-presentation; cross-priming; immunotherapy; surgery; CYTOREDUCTIVE NEPHRECTOMY; ADJUVANT THERAPY; GM-CSF; SURGERY; INTERLEUKIN-2; CHEMOTHERAPY; MEMORY; DIFFERENTIATION; IMMUNOTHERAPY; INTERFERON;
D O I
10.4161/onci.20924
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An incomplete understanding on the effect of surgery on tumor-specific immunity continues to hamper efforts to combine surgery with immunotherapy in the clinic. Herein, we describe the impact of tumor resection on the tumor-specific T-cell response, showing that complete tumor resection is associated with (1) a decline in the amount of cross-presented tumor antigens, (2) a decline of cytolytic tumor-specific CD8(+) T-cell activity, and (3) the development of systemic CD8(+) T-cell-mediated protective immunity. Our findings are consistent with a model whereby tumor resection releases antitumor CD8(+) T cells from chronic antigen exposure, allowing a gradual differentiation toward functional antitumor memory T cells. This process depends on sentinel lymph nodes, as their removal at the time of surgery was associated with a strong negative effect on survival. We conclude that complete tumor resection provides a unique environment that boosts protective immunological memory and might provide a powerful platform for immunotherapy. Our findings also carry important implications for the design and timing of post-surgery immunotherapeutic regimens.
引用
收藏
页码:1084 / 1094
页数:11
相关论文
共 50 条
  • [1] Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope
    Otahal, P
    Hutchinson, SC
    Mylin, LM
    Tevethia, MJ
    Tevethia, SS
    Schell, TD
    JOURNAL OF IMMUNOLOGY, 2005, 175 (02): : 700 - 712
  • [2] Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance
    Berg, Martina
    Wingender, Gerhard
    Djandji, Dominik
    Hegenbarth, Silke
    Momburg, Frank
    Hämmerling, Guenter
    Limmer, Andreas
    Knolle, Percy
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (11) : 2960 - 2970
  • [3] Tracking tumor-specific CD8+ T cell responses
    Burke, Kelly P.
    Markson, Samuel C.
    Sharpe, Arlene H.
    TRENDS IN IMMUNOLOGY, 2023, 44 (05) : 326 - 328
  • [4] Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
    Nowak, AK
    Lake, RA
    Marzo, AL
    Scott, B
    Heath, WR
    Collins, EJ
    Frelinger, JA
    Robinson, BWS
    JOURNAL OF IMMUNOLOGY, 2003, 170 (10): : 4905 - 4913
  • [5] Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response
    Khong, Hiep
    Volmari, Annika
    Sharma, Meenu
    Dai, Zhimin
    Imo, Chinonye S.
    Hailemichael, Yared
    Singh, Manisha
    Moore, Derek T.
    Xiao, Zhilan
    Huang, Xue-fei
    Horvath, Thomas D.
    Hawke, David H.
    Overwijk, Willem W.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (10): : 3464 - 3474
  • [6] Enhancing antigen cross-presentation and CD8+ T cell responses by adsorbing antigen to nanoparticles
    Huete-Carrasco, J.
    Munoz-Wolf, N.
    Ward, R. W.
    Lavelle, E. C.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 4 - 4
  • [7] NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors
    Fan, ZS
    Yu, P
    Wang, Y
    Wang, YG
    Fu, ML
    Liu, WH
    Sun, YL
    Fu, YX
    BLOOD, 2006, 107 (04) : 1342 - 1351
  • [8] Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer
    Karanikas, Vaios
    Zamanakou, Maria
    Soukou, Faye
    Kerenidi, Theodora
    Gourgoulianis, Konstantinos I.
    Germenis, Anastasios E.
    IMMUNOLOGY AND CELL BIOLOGY, 2010, 88 (05): : 575 - 585
  • [9] Generation of tumor-specific T-cell therapies
    Morris, E
    Hart, D
    Gao, LQ
    Tsallios, A
    Xue, SA
    Stauss, H
    BLOOD REVIEWS, 2006, 20 (02) : 61 - 69
  • [10] Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens
    Miller, JFAP
    Kurts, C
    Allison, J
    Kosaka, H
    Carbone, F
    Heath, WR
    IMMUNOLOGICAL REVIEWS, 1998, 165 : 267 - 277